Biotalys’ first proteinbased biocontrol shows up in vineyards

Based on data from the latest trials in grapes across vineyards in diverse climates throughout California and New York, Biotalys’ biocontrol product Evoca provided superior preventative control of Botrytis bunch rot in grapevines compared to chemical standard. Approval is estimated within this year.

Read more

Andera Partners co-leads $118m Series B of Mineralys thx (USA)

Andera Partners, Paris based European private equity player, announced on Wednesday that, together with RA Capital Management, it is leading an oversubscribed and up-sized $118m Series B financing for Mineralys Therapeutics, Inc., Philadelphia (USA), a private, clinical-stage biopharmaceutical company  developing novel therapy for the treatment of hypertension.

Read more

From waste to sugar – demonstration plant opens in Wales

The South Wales-based demonstration plant "VAMOS" that generates industrial biotechnology sugars and other recycled material streams from the paper and card in mixed household waste has come online these days. The products will be used in the production of several high-performance bio-based materials.

Read more

International Vaccine Institute – IVI – will locate its European office in Stockholm

The International Vaccine Institute, IVI, which is associated with the WHO and UN, will locate its European office in Stockholm. To date, the institute is only located in the host country of South Korea.

Read more

Abliva decides on a SEK200m financing to fund Phase 2/3 study

The financing (around €19m) shall fully fund the commencement of a potentially pivotal/registrational Phase 2/3 study for KL1333 and its progression to the outcome of a key interim analysis.

Read more

Transine Therapeutics Ltd closes £13.7m seed financing

Transine Therapeutics Ltd has added £4.6m from lead investor Epidarex Capital and the Dementia Discovery Fund (DDF) to its £9.1m seed funding led by Takeda Ventures and DDF. 

Read more

Orphan drug developer Minoryx raises €51m

Minoryx Therapeutics SL has closed a €51m financing, including Series C equity financing and complementary bank debt to commercialise X-ALD drug leriglitazone.

Read more

G7 heads call for decarbonisation of industry

G7 Climate, Energy and Environment Ministers have announced a wide range of actions to tackle “the triple global crisis of climate change, biodiversity loss and pollution".
 

Read more

Ellipses Pharma licences SRB22 from SunRock Biopharma

Ellipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein set to eliminate solid tumours.

Read more